Tradestie Institutional Equity Comparison Engine
EVGN vs CGEN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGEN Overall Edge
CGEN Captures Institutional Edge (4โ0 Pillars ยท 10โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, EVGN trades at N/M Forward P/E with -858.2% operating margin (-60.7% YoY revenue) versus CGEN at 12.4x Forward P/E and 41.3% operating margin (+102.1% YoY). In options structure, EVGN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CGEN
EVGN N/M vs CGEN 12.4x Fwd P/E
Growth & Margin Winner
CGEN
Op Margin -858.2% vs 41.3% ยท YoY -60.7% vs +102.1%
Momentum & Technical Winner
CGEN
1Y -71.9% vs +23.2% ยท 52W Pos 9% vs 33%
Options & Structure Winner
CGEN
UNCLASSIFIED (N/A IV) vs BREAKDOWN (57th %ile IV)
EVGN
NASDAQ
Evogene Ltd.
Agricultural Chemicals
$0.34
-13.17% 1D
Market Cap
$6.0M
1M Return
-7.58%
1Y Return
-71.89%
Forward P/E
N/M
Unified AI Score
44.1 / 100
HOLD
Tech 42.0
Fund 44.0
Flow 50.0
Mom 60.0
CGEN
NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap
$193.2M
1M Return
+2.54%
1Y Return
+23.17%
Forward P/E
12.4x
Unified AI Score
49.8 / 100
HOLD
Tech 53.0
Fund 52.0
Flow 55.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
EVGN -71.89%
CGEN +23.17%
Spread: +95.06 pp (CGEN Lead)
Pillar 3 Annualized Quarterly Run-Rate Revenue & Operating Margin Trajectory (USD-Normalized)
| Period | EVGN Revenue | CGEN Revenue | EVGN Op. Margin | CGEN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| Q3 '25 | $0M | $10M | -873.1% | -417.4% | CGEN |
| Q4 '25 | $0M | $270M | -1659.9% | 83.2% | CGEN |
| Q1 '26 | $0M | $10M | -943.1% | -414.4% | CGEN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EVGN | CGEN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.0M | $193.2M | Larger Scale | CGEN |
| Trailing P/E Ratio Valuation | N/M | 5.2x | Lower Multiple | CGEN |
| Forward P/E Ratio Valuation | N/M | 12.4x | Lower Multiple | CGEN |
| Revenue Growth (YoY) Growth | -60.7% | +102.1% | Higher Growth | CGEN |
| Operating Margin (TTM) Profitability | -858.2% | 41.3% | Higher Margin | CGEN |
| Net Profit Margin Profitability | 0.0% | 47.9% | Higher Margin | CGEN |
| Return on Equity (ROE) Capital Efficiency | -182.8% | 57.2% | Higher ROE | CGEN |
| 52-Week Range Position Momentum | 9% ($0โ$1) | 33% ($1โ$3) | Stronger Trend | CGEN |
| Beta / 30D Volatility Risk Regime | 1.37ฮฒ ยท 138% Vol | 1.44ฮฒ ยท 62% Vol | Lower Realized Risk | CGEN |
| Unified Institutional Score Composite Signal | 44.1 / 100 (HOLD) | 49.8 / 100 (HOLD) | Higher Composite | CGEN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full EVGN vs CGEN Buy Guide
EVGN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CGEN
BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
57th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither EVGN nor CGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.